We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Antigen Testing for SARS-CoV-2 Could Effectively Control COVID-19 Outbreak, Finds Study

By LabMedica International staff writers
Posted on 30 Aug 2021
Print article
Illustration
Illustration
Rapid COVID-19 antigen tests that permit new cases to isolate immediately can be important surveillance tools and effectively control COVID-19 outbreaks, according to a longitudinal comparison between antigen tests performed at home and quantitative real-time polymerase chain reaction (qRT-PCR).

Researchers at E25Bio, Inc. (Boston, MA, USA), LabCentral, Inc. (Boston, MA, USA), Harvard T. H. Chan School of Public Health (Boston, MA, USA), Mount Sinai School of Medicine (New York, NY, USA), and BioInnovation Labs, LLC (Cambridge, MA, USA) sought to validate the effectiveness of direct antigen rapid tests (DARTs) and to test whether at-home testing with DART could prevent the spread of SARS-CoV-2 in a co-working environment. The team conducted a study of high-frequency testing using inexpensive, at-home, semi-quantitative, DARTs and compared their performance with that of qRT-PCR on self-collected nasal specimens.

For the study, a total of 257 participants were enrolled who self-collected nasal swab specimens twice weekly at home during a six-month period. DART was performed at home, and the findings were compared with laboratory qRT-PCR tests. A total of 2,951 pairs of nasal swabs were self-collected by participants and tested by qRT-PCR and DART. The researchers found that that twice-weekly surveillance with DART detected infections in 15 individuals, with 96.3% sensitivity on days 0 through 3 of symptoms. Detection on day 3 is almost as effective as detection on day 1 for reducing the incidence of COVID-19, if 75% of a population is surveilled. The prevalence of disease dictates the frequency of testing and its effectiveness for controlling potential outbreaks.

COVID-19 outbreak management has been hindered by high transmission rates and limitations in testing capacity. Effective public health tools are needed for rapid and early detection. The current diagnostic standard is qRT-PCR, although its cost and long turnaround times limit its utility for widespread surveillance. However, frequent at-home testing with DART allows infected individuals to be identified and quarantined immediately. Such surveillance can prevent viral transmission in in-person work environments or other social settings, effectively controlling COVID-19 outbreaks, according to the researchers.

Related Links:
E25Bio, Inc.
LabCentral, Inc.
Harvard T. H. Chan School of Public Health
Mount Sinai School of Medicine
BioInnovation Labs, LLC


Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more